Equities

Nymox Pharmaceutical Corp

NYMXF:PKC

Nymox Pharmaceutical Corp

Actions
  • Price (USD)0.05
  • Today's Change0.009 / 21.95%
  • Shares traded15.96k
  • 1 Year change-95.00%
  • Beta8.5382
Data delayed at least 15 minutes, as of Nov 12 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.071.400.83
Total Receivables, Net0.010.010.01
Total Inventory--00.03
Prepaid expenses0.020.020.13
Other current assets, total0.530.030.03
Total current assets0.631.461.04
Property, plant & equipment, net0.000.170.41
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets0.631.631.44
LIABILITIES
Accounts payable3.021.701.27
Accrued expenses0.030.240.29
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.170.23
Other current liabilities, total0.7500
Total current liabilities3.802.111.79
Total long term debt000.16
Total debt00.170.39
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities3.802.111.95
SHAREHOLDERS EQUITY
Common stock174172165
Additional paid-in capital282728
Retained earnings (accumulated deficit)(208)(199)(193)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total3.210(0.59)
Total equity(3.17)(0.48)(0.51)
Total liabilities & shareholders' equity0.631.631.44
Total common shares outstanding949186
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.